Scientific Programme
 |
12:45 - 14:15 Poster Session 2 - Testis tumours
| 49: Cell-free DNA in serum: A novel diagnostic marker for patients with testicular cancer J. Ellinger, Bonn (DE) |
| 50: Expression of the inhibitor of apoptosis Livin in testicular germ cell tumours: Correlations with clinicopathological tumour features C. Kempkensteffen, Berlin (DE) |
| 51: Immunohistochemistry on testicular biopsies is mandatory for carcinoma in situ diagnosis, both in a specialized- and routine-pathology setting: OCT3/4 as informative marker N. Van Casteren, Rotterdam (NL) |
| 52: Serum proteomic profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry in testicular germ cell cancer patients R. Strenziok, Berlin (DE) |
| 53: The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma S. Hinz, Berlin (DE) |
| 54: Randomised phase III trial comparing retroperitoneal lymph node dissection (RPLND) with one course of bleomycin, etoposide, cisplatin (BEP) chemotherapy in patients with stage I non-seminomatous germ cell tumour patients (NSGCT) - updated results of AUO t R. Siener, Düsseldorf (DE) |
| 55: Risk of distant metastasis following retroperitoneal lymph-node dissection (RPLND) alone in clinical stage I (CS I) non-seminomatous germ cell testicular tumours (NSGCTTs) N. Nicolai, Milan (IT) |
| 56: 2 cycles cisplatin-based chemotherapy for low volume retroperitoneal stage ii nonseminomatous germ cell tumours H. Steiner, Innsbruck (AT) |
| 57: Sperm analysis after adjuvant single-agent carboplatin therapy for stage I seminoma N.J. Leonhartsberger, Innsbruck (AT) |
| 58: Bilateral laparoscopic retroperitoneal lymph node dissection H. Steiner, Innsbruck (AT) |
| 59: Operative morbidity in laparoscopic retroperitoneal lymph-node dissection in clinical stage a non-seminomatous testis cancer J.P. Rioja Zuazu, Zaragoza (ES) |
| 60: Non-risk adapted surveillance in stage I non-seminomatous germ cell tumours (NSGCT): Improved recent outcomes M. Jewett, Toronto (CA) |
| 61: Excellent long-term oncological outcome after elective testis-sparing surgery for Leydig cell tumours: A single-centre experience with 19 cases G. Giannarini, Pisa (IT) |
| 62: Sexuality and partnership in patients with testicular cancer- a research of 131 cases A. Martinschek, Ulm (DE) |
| 63: Comparison between questionnaires to laboratory findings in the follow-up of testicular cancer survivors J.E. Lackner, Vienna (AT) |
| 64: Quality of life after surgical resection of retroperitoneal residual masses: Concordance with anatomical location N. Doumerc, Toulouse (FR) |